A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals

Virus Research

Volumn 131, Issue 2, 2008, Pages 260-270

  Franco, Sandra ^a   Clotet, Bonaventura ^a   Martínez, Miguel Angel ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Catalytic efficiency; Genotype; HCV; NS3 protease

Indexed keywords

ADAPTOR PROTEIN; BETA INTERFERON; INTERFERON REGULATORY FACTOR 3; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PROTEIN CARDIF; PROTEIN TRIF; PROTEINASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

AMINO ACID SEQUENCE; ARTICLE; CATALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MOLECULAR INTERACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; CARRIER PROTEINS; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR SEQUENCE DATA; RNA, VIRAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS); VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

HEPATITIS C VIRUS;

EID: 38649125211     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2007.10.003     Document Type: Article

References (66)

1. Alter H.J. To C or not to C: these are the questions. Blood 85 7 (1995) 1681-1695
2. Appel N., Schaller T., Penin F., and Bartenschlager R. From structure to function: new insights into hepatitis C virus RNA replication. J. Biol. Chem. 281 15 (2006) 9833-9836
3. Ballesteros A.L., Franco S., Fuster D., Planas R., Martinez M.A., Acosta L., Sirera G., Salas A., Tor J., Rey-Joly C., Clotet B., and Tural C. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS 18 1 (2004) 59-66
4. Bartenschlager R., Ahlbornlaake L., Mous J., and Jacobsen H. Kinetic and structural-analyses of hepatitis-C virus polyprotein processing. J. Virol. 68 8 (1994) 5045-5055
5. Bogen S.L., Arasappan A., Bennett F., Chen K., Jao E., Liu Y.T., Lovey R.G., Venkatraman S., Pan W., Parekh T., Pike R.E., Ruan S., Liu R., Baroudy B., Agrawal S., Chase R., Ingravallo P., Pichardo J., Prongay A., Brisson J.M., Hsieh T.Y., Cheng K.C., Kemp S.J., Levy O.E., Lim-Wilby M., Tamura S.Y., Saksena A.K., Girijavallabhan V., and Njoroge F.G. Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J. Med. Chem. 49 9 (2006) 2750-2757
6. Breiman A., Grandvaux N., Lin R.T., Ottone C., Akira S., Yoneyama M., Fujita T., Hiscott J., and Meurs E.F. Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKK epsilon. J. Virol. 79 7 (2005) 3969-3978
7. Cabana M., Fernandez G., Parera M., Clotet B., and Martinez M.A. Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions. Virology 300 1 (2002) 71-78
8. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri A., Morand P., Goujard C., Pialoux G., Piroth L., Salmon-Ceron D., Degott C., Cacoub P., and Perronne C. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292 23 (2004) 2839-2848
9. Cheng G., Zhong J., and Chisari F.V. Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA 103 22 (2006) 8499-8504
10. Choo Q.L., Richman K.H., Han J.H., Berger K., Lee C., Dong C., Gallegos C., Coit D., Medina-Selby R., Barr P.J., et al. Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. USA 88 6 (1991) 2451-2455
11. Dimasi N., Pasquo A., Martin F., Di Marco S., Steinkuhler C., Cortese R., and Sollazzo M. Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein. Protein Eng. 11 12 (1998) 1257-1265
12. Failla C., Tomei L., and Defrancesco R. Both Ns3 and Ns4a are required for proteolytic processing of hepatitis-C virus nonstructural proteins. J. Virol. 68 6 (1994) 3753-3760
13. Fernandez G., Clotet B., and Martinez M.A. Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. J. Virol. 81 5 (2007) 2485-2496
14. Ferreon J.C., Ferreon A.C., Li K., and Lemon S.M. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J. Biol. Chem. 280 21 (2005) 20483-20492
15. Foy E., Li K., Wang C., Sumpter Jr. R., Ikeda M., Lemon S.M., and Gale Jr. M. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300 5622 (2003) 1145-1148
16. Franco S., Parera M., Aparicio E., Clotet B., and Martinez M.A. Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology 45 4 (2007) 899-910
17. Franco S., Tural C., Clotet B., and Martinez M.A. Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1. Virus Res. 123 2 (2007) 161-169
18. Goudreau N., and Llinas-Brunet M. The therapeutic potential of NS3 protease inhibitors in HCV infection. Expert Opin. Investig. Drugs 14 9 (2005) 1129-1144
19. Hijikata M., Mizushima H., Akagi T., Mori S., Kakiuchi N., Kato N., Tanaka T., Kimura K., and Shimotohno K. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J. Virol. 67 8 (1993) 4665-4675
20. Holland-Staley C.A., Kovari L.C., Golenberg E.M., Pobursky K.J., and Mayers D.L. Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Arch. Virol. 147 7 (2002) 1385-1406
21. Huang Z., Murray M.G., and Secrist III J.A. Recent development of therapeutics for chronic HCV infection. Antiviral Res. 71 2-3 (2006) 351-362
22. Johnson C.L., Owen D.M., and Gale Jr. M. Functional and therapeutic analysis of hepatitis C virus NS3{middle dot}4A protease control of antiviral immune defense. J. Biol. Chem. 282 14 (2007) 10792-10803
23. Kim J.L., Morgenstern K.A., Lin C., Fox T., Dwyer M.D., Landro J.A., Chambers S.P., Markland W., Lepre C.A., Omalley E.T., Harbeson S.L., Rice C.M., Murcko M.A., Caron P.R., and Thomson J.A. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87 2 (1996) 343-355
24. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Bos M., Cameron D.R., Cartier M., Cordingley M.G., Faucher A.M., Goudreau N., Kawai S.H., Kukolj G., Lagace L., LaPlante S.R., Narjes H., Poupart M.A., Rancourt J., Sentjens R.E., St George R., Simoneau B., Steinmann G., Thibeault D., Tsantrizos Y.S., Weldon S.M., Yong C.L., and Llinas-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 6963 (2003) 186-189
25. Lin C., Gates C.A., Rao B.G., Brennan D.L., Fulghum J.R., Luong Y.P., Frantz J.D., Lin K., Ma S., Wei Y.Y., Perni R.B., and Kwong A.D. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. 280 44 (2005) 36784-36791
26. Lin C., Lin K., Luong Y.P., Rao B.G., Wei Y.Y., Brennan D.L., Fulghum J.R., Hsiao H.M., Ma S., Maxwell J.P., Cottrell K.M., Perni R.B., Gates C.A., and Kwong A.D. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279 17 (2004) 17508-17514
27. Lin C., Thomson J.A., and Rice C.M. A central region in the hepatitis-C virus Ns4a protein allows formation of an active Ns3-Ns4a serine proteinase complex in vivo and in vitro. J. Virol. 69 7 (1995) 4373-4380
28. Lin K., Perni R.B., Kwong A.D., and Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob. Agents Chemother. 50 5 (2006) 1813-1822
29. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., and Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 309 5734 (2005) 623-626
30. Lodrini S., Bagaglio S., Canducci F., De Mitri M.S., Andreone P., Loggi E., Lazzarin A., Clementi M., and Morsica G. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus. J. Biol. Regul. Homeost. Agents 17 2 (2003) 198-204
31. Lohmann V., Korner F., Dobierzewska A., and Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75 3 (2001) 1437-1449
32. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., and Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 5424 (1999) 110-113
33. Loo Y.M., Owen D.M., Li K., Erickson A.K., Johnson C.L., Fish P.M., Carney D.S., Wang T., Ishida H., Yoneyama M., Fujita T., Saito T., Lee W.M., Hagedorn C.H., Lau D.T., Weinman S.A., Lemon S.M., and Gale Jr. M. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 103 15 (2006) 6001-6006
34. Lorenz I.C., Marcotrigiano J., Dentzer T.G., and Rice C.M. Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 442 7104 (2006) 831-835
35. Lu L., Pilot-Matias T.J., Stewart K.D., Randolph J.T., Pithawalla R., He W., Huang P.P., Klein L.L., Mo H., and Molla A. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48 6 (2004) 2260-2266
36. Malcolm B.A., Liu R., Lahser F., Agrawal S., Belanger B., Butkiewicz N., Chase R., Gheyas F., Hart A., Hesk D., Ingravallo P., Jiang C., Kong R., Lu J., Pichardo J., Prongay A., Skelton A., Tong X., Venkatraman S., Xia E., Girijavallabhan V., and Njoroge F.G. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob. Agents Chemother. 50 3 (2006) 1013-1020
37. Martinez M.A., Cabana M., Parera M., Gutierrez A., Este J.A., and Clotet B. A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 44 5 (2000) 1132-1139
38. Martinez M.A., and Clotet B. Genetic screen for monitoring hepatitis C virus NS3 serine protease activity. Antimicrob. Agents Chemother. 47 5 (2003) 1760-1765
39. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., and Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437 7062 (2005) 1167-1172
40. Moradpour D., Penin F., and Rice C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5 6 (2007) 453-463
41. Parera M., Clotet B., and Martinez M.A. Genetic screen for monitoring severe acute respiratory syndrome coronavirus 3C-like protease. J. Virol. 78 24 (2004) 14057-14061
42. Parera M., Fernandez G., Clotet B., and Martinez M.A. HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions. Mol. Biol. Evol. 24 2 (2007) 382-387
43. Pawlotsky J.M. Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol. 299 (2006) 261-284
44. Perni R.B., Almquist S.J., Byrn R.A., Chandorkar G., Chaturvedi P.R., Courtney L.F., Decker C.J., Dinehart K., Gates C.A., Harbeson S.L., Heiser A., Kalkeri G., Kolaczkowski E., Lin K., Luong Y.P., Rao B.G., Taylor W.P., Thomson J.A., Tung R.D., Wei Y., Kwong A.D., and Lin C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50 3 (2006) 899-909
45. Poynard T., Yuen M.F., Ratziu V., and Lai C.L. Viral hepatitis C. Lancet 362 9401 (2003) 2095-2100
46. Quer J., Esteban J.I., Cos J., Sauleda S., Ocana L., Martell M., Otero T., Cubero M., Palou E., Murillo P., Esteban R., and Guardia J. Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection. J. Virol. 79 24 (2005) 15131-15141
47. Reed K.E., Grakoui A., and Rice C.M. Hepatitis C virus-encoded NS2-3 protease: cleavage-site mutagenesis and requirements for bimolecular cleavage. J. Virol. 69 7 (1995) 4127-4136
48. Reesink H.W., Zeuzem S., Weegink C.J., Forestier N., van Vliet A., van de Wetering de Rooij J., McNair L., Purdy S., Kauffman R., Alam J., and Jansen P.L. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131 4 (2006) 997-1002
49. Saito T., Hirai R., Loo Y.M., Owen D., Johnson C.L., Sinha S.C., Akira S., Fujita T., and Gale Jr. M. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc. Natl. Acad. Sci. USA 104 2 (2007) 582-587
50. Sarrazin C., Kieffer T.L., Bartels D., Hanzelka B., Muh U., Welker M., Wincheringer D., Zhou Y., Chu H.M., Lin C., Weegink C., Reesink H., Zeuzem S., and Kwong A.D. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132 5 (2007) 1767-1777
51. Sarrazin C., Mihm U., Herrmann E., Welsch C., Albrecht M., Sarrazin U., Traver S., Lengauer T., and Zeuzem S. Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection. J. Infect. Dis. 192 10 (2005) 1710-1719
52. Sarrazin C., Rouzier R., Wagner F., Forestier N., Larrey D., Gupta S.K., Hussain M., Shah A., Cutler D., Zhang J., and Zeuzem S. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132 4 (2007) 1270-1278
53. Stoddart C.A., Liegler T.J., Mammano F., Linquist-Stepps V.D., Hayden M.S., Deeks S.G., Grant R.M., Clavel F., and McCune J.M. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat. Med. 7 6 (2001) 712-718
54. Tellinghuisen T.L., Evans M.J., von Hahn T., You S., and Rice C.M. Studying hepatitis C-making the best out of a bad virus. J. Virol. 23 May (2007) (Epub ahead of print)
55. Thomson J.A., and Perni R.B. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. Curr. Opin. Drug Discov. Dev. 9 5 (2006) 606-617
56. Tomei L., Failla C., Santolini E., De Francesco R., and La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol. 67 7 (1993) 4017-4026
57. Tomei L., Failla C., Vitale R.L., Bianchi E., and De Francesco R. A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease. J. Gen. Virol. 77 Pt 5 (1996) 1065-1070
58. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., and Malcolm B.A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 70 2 (2006) 28-38
59. Vallet S., Gouriou S., Nousbaum J.B., Legrand-Quillien M.C., Goudeau A., and Picard B. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. J. Med. Virol. 75 4 (2005) 528-537
60. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., and Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11 7 (2005) 791-796
61. Winters M.A., Welles S.L., and Holodniy M. Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus. J. Virol. 80 8 (2006) 4196-4199
62. Wohnsland A., Hofmann W.P., and Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin. Microbiol. Rev. 20 1 (2007) 23-38
63. Wright-Minogue J., Yao N., Zhang R., Butkiewicz N.J., Baroudy B.M., Lau J.Y., and Hong Z. Cross-genotypic interaction between hepatitis C virus NS3 protease domains and NS4A cofactors. J. Hepatol. 32 3 (2000) 497-504
64. Yi M., Tong X., Skelton A., Chase R., Chen T., Prongay A., Bogen S.L., Saksena A.K., Njoroge F.G., Veselenak R.L., Pyles R.B., Bourne N., Malcolm B.A., and Lemon S.M. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J. Biol. Chem. 281 12 (2006) 8205-8215
65. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., and Chisari F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 102 26 (2005) 9294-9299
66. Zhou Y., Muh U., Hanzelka B.L., Bartels D.J., Wei Y., Rao B.G., Brennan D.L., Tigges A.M., Swenson L., Kwong A.D., and Lin C. Phenotypic and structural analyses of HCV NS3 protease ARG155 variants: Sensitivity to telaprevir (VX-950) and interferon alpha. J. Biol. Chem. 6 June (2007) (Epub ahead of print)